AR and neoplasm: Although androgen deprivation therapy (ADT) directly targeting AR-expressing tumor cells is still the first-line treatment for advanced prostate cancer5, it eventually fails in most patients who consequently develop castration resistant prostate cancer (CRPC), an incurable disease2,6.